MARKET

ACER

ACER

Acer Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.500
-0.130
-3.58%
After Hours: 3.430 -0.07 -2.00% 17:19 07/10 EDT
OPEN
3.680
PREV CLOSE
3.630
HIGH
3.690
LOW
3.330
VOLUME
208.87K
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
1.080
MARKET CAP
35.87M
P/E (TTM)
-1.3383
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACER stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.

EPS

ACER News

More
Acer Therapeutics rallies on encouraging ACER-001 data
Seeking Alpha - Article · 1d ago
CLNE, NTES among premarket gainers
Seeking Alpha - Article · 1d ago
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 1d ago
Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study
GlobeNewswire · 2d ago
Acer Therapeutics Announces Administration Of ACER-001 In A Fasted State Increased Systemic Exposure Of Phenylbutyrate In Healthy Volunteer Food Effect Study
Model suggests ACER-001, Acer’s taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with Urea Cycle Disorders compared to current
Benzinga · 2d ago
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Acer Therapeutics Inc. Investors (ACER)
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. ("Acer" or the "Company") (NASDAQ: ACER) concerning whether the board breached its fiduciary duties to shareholders.
Business Wire · 06/24 17:53
Ultragenyx Pharmaceutical: Near-Term Catalysts Offer Best Of Both Worlds
Seeking Alpha - Article · 06/16 15:00
Is Acer Therapeutics Inc. (ACER) A Good Stock To Buy?
Insider Monkey · 05/29 17:44

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About ACER

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
More

Webull offers kinds of Acer Therapeutics Inc stock information, including NASDAQ:ACER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACER stock methods without spending real money on the virtual paper trading platform.